Core Insights - MSCI announced the results of its index review for November 2025, with adjustments effective after the market close on November 24 [1] - Kintor Pharmaceutical (stock code: 2171.HK) has been added to the MSCI Global Small Cap Index, transitioning from the MSCI Hong Kong Small Cap Index to the China region index [1] - Inclusion in MSCI indices is seen as a signal of recognition by global capital markets, potentially attracting passive fund allocations and enhancing liquidity for the company [1] Company Overview - Kintor Pharmaceutical is a leading player in the CGT (Cell and Gene Therapy) sector in China, focusing on innovative CAR-T cell therapies for treating hematological malignancies and solid tumors [1] - The company aims to address key challenges in the CAR-T field, including tackling hard-to-treat tumors and reducing treatment costs to make therapies more accessible to the public [1] - The inclusion in the MSCI Global Small Cap Index is expected to increase global investor attention on Kintor Pharmaceutical, further enhancing its stock liquidity and market valuation [1]
科济药业纳入MSCI全球小盘股中国地区指数